Cargando…
Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role?
The disease caused by the new coronavirus SARS-CoV-2 (COVID-19) is currently spread worldwide . Recent data supports SARS-CoV-2 may use integrins to enter human cells. Therefore, anti-integrins therapies might be an alternative against the infection . Natalizumab, approved for Multiple Sclerosis (MS...
Autores principales: | Aguirre, Clara, Meca-Lallana, Virginia, Barrios-Blandino, Ana, del Río, Beatriz, Vivancos, Jose |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831671/ https://www.ncbi.nlm.nih.gov/pubmed/32531754 http://dx.doi.org/10.1016/j.msard.2020.102250 |
Ejemplares similares
-
Establishment of a safety protocol for the administration of treatments in multiple sclerosis during the SARS-CoV-2 pandemic
por: Meca-Lallana, Virginia, et al.
Publicado: (2020) -
COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies
por: Meca-Lallana, Virginia, et al.
Publicado: (2020) -
Analysis of humoral and cellular immunity after SARS-CoV-2 vaccination in patients with multiple sclerosis treated with immunomodulatory drugs
por: Meca-Lallana, Virginia, et al.
Publicado: (2023) -
Evaluation of Natalizumab Pharmacokinetics and Pharmacodynamics: Toward Individualized Doses
por: Serra López-Matencio, Jose M., et al.
Publicado: (2021) -
Cost-Analysis of Subcutaneous vs Intravenous Administration of Natalizumab Based on Patient Care Pathway in Multiple Sclerosis in Spain
por: Alonso Torres, A. M., et al.
Publicado: (2023)